Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Selective Depletion of CD45RA+ T Cells From Allogeneic Peripheral Blood Stem Cell Grafts for Prevention of GVHD
NCT02220985Phase 2Completed
- Sponsor
- Fred Hutchinson Cancer Center
- Start
- Mar 2015
- Primary completion
- Apr 2025
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label trial in acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), myelodysplastic syndrome (MDS) and 1 more (4 arms), sponsored by Fred Hutchinson Cancer Center. Primary endpoints: Chronic Graft-Versus-Host Disease at 5 years, Time to Completion of Prednisone at 5 years and 4 more. Started Mar 2015; status: completed.
02
Conditions
acute lymphoblastic leukemia (ALL)acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)chronic myeloid leukemia (CML)
Beyond the preview
Go deeper on NCT02220985.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02220985.